Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis

被引：6

作者：

Yi, Jun Ho ^{[1
]}

Kim, Seok Jin ^{[2
]}

Yoon, Dok Hyun ^{[3
]}

Suh, Cheolwon ^{[3
]}

Chang, Myung Hee ^{[4
]}

Yang, Deok Hwan ^{[5
]}

Jo, Jae-Cheol ^{[6
]}

Hyun, Shin Young ^{[7
]}

Eom, Hyeon-Seok ^{[8
]}

Lee, Jeong-Ok ^{[9
]}

Kwon, Ji Hyun ^{[10
]}

Han, Sang Hoon ^{[11
]}

Lee, Seung-Shin ^{[12
]}

Kwak, Jae-Yong ^{[13
]}

Kim, Se Hyung ^{[14
]}

Kim, Dae Sik ^{[15
]}

Lee, Ji Hyun ^{[16
]}

Oh, Sung Yong ^{[16
]}

Ryoo, Hun Mo ^{[17
]}

Kim, Hyo Jung ^{[18
]}

Kim, Won Seog ^{[2
]}

机构：

[1] Chung Ang Univ, Div Hematol Oncol, Dept Med, Seoul 06973, South Korea

[2] Sungkyunkwan Univ, Div Hematol & Oncol, Dept Med, Samsung Med Ctr,Sch Med, 50 Irwon Dong, Seoul 06351, South Korea

[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul 05505, South Korea

[4] Natl Hlth Insurance Corp Ilsan Hosp, Goyang 10444, South Korea

[5] Chonnam Natl Univ, Sch Med, Dept Hematooncol, Hwasun Hosp, Hwasun 58128, Gwangju, South Korea

[6] Univ Ulsan, Dept Hematol & Oncol, Ulsan Univ Hosp, Coll Med, Ulsan 44033, South Korea

[7] Yonsei Univ, Dept Internal Med, Coll Med, Wonju 26426, South Korea

[8] Natl Canc Ctr, Dept Internal Med, Gyeonggi Do 10408, Goyang, South Korea

[9] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam 13620, South Korea

[10] ChungBuk Natl Univ Hosp, Dept Internal Med, Chungbuk 28644, Cheongju, South Korea

[11] Jeju Natl Univ, Dept Internal Med, Jeju Natl Univ Hosp, Sch Med, Jeju 63241, South Korea

[12] Wonkwang Univ Hosp, Dept Hematol Oncol, Iksan 54538, South Korea

[13] Jeonbuk Natl Univ, Dept Internal Med, Sch Med, Jeonju 54907, South Korea

[14] Soonchunhyang Univ, Div Hematol Oncol, Dept Internal Med, Coll Med,Bucheon Hosp, Bucheon 14584, South Korea

[15] Korea Univ, Div Hematol Oncol, Dept Internal Med, Guro Hosp, Seoul 08308, South Korea

[16] Dong A Univ, Div Hematol Oncol, Dept Internal Med, Coll Med, Busan 49201, South Korea

[17] Catholic Univ Daegu, Dept Internal Med, Div Hematol Oncol, Daegu 42472, South Korea

[18] Hallym Univ, Div Hematol Oncol, Dept Internal Med, Sacred Heart Hosp,Coll Med, Anyang 14068, South Korea

来源：

CANCER COMMUNICATIONS | 2021年 / 41卷 / 03期

关键词：

D O I：

10.1002/cac2.12150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：275 / 278

页数：4

共 50 条

[1] Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis
Yi, J. H.
Kim, W. S.
Kim, S. J.
Yoon, D. H.
Suh, C.
Chang, M. H.
Yang, D. H.
Jo, J-C.
Hyun, S. Y.
Eom, H-S.
Lee, J-O.
Kwon, J. H.
Han, S. H.
Lee, S-S.
Kwak, J-Y.
Kim, S. H.
ANNALS OF ONCOLOGY, 2019, 30
[2] Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience
Jeon, Young-Woo
Yoon, Seugyun
Min, Gi June
Park, Sung-Soo
Park, Silvia
Yoon, Jae-Ho
Lee, Sung-Eun
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Kim, Hee-Je
Lee, Seok
Min, Chang-Ki
Lee, Jong Wook
Cho, Seok-Goo
CANCER MEDICINE, 2019, 8 (16): : 6860 - 6870
[3] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
Lee, Yong-Pyo
Jung, Ye Ji
Cho, Junhun
Ko, Young Hyeh
Kim, Won Seog
Kim, Seok Jin
Yoon, Sang Eun
BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
[4] REAL-WORLD TREATMENT OUTCOMES AMONG RELAPSED/REFRACTORY PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH IBRUTINIB OR ACALABRUTINIB
Crawford, S.
Lafeuille, M. H.
Emond, B.
Harb, D.
Voladarsky, R.
Chen, N.
Karve, S.
VALUE IN HEALTH, 2023, 26 (06) : S403 - S403
[5] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study
Epperla, Narendranath
Hamadani, Mehdi
Cashen, Amanda F.
Ahn, Kwang W.
Oak, Eunhye
Kanate, Abraham S.
Calzada, Oscar
Cohen, Jonathon B.
Farmer, Luke
Ghosh, Nilanjan
Tallarico, Michael
Nabhan, Chadi
Costa, Luciano J.
Kenkre, Vaishalee P.
Hari, Parameswaran N.
Fenske, Timothy S.
HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 528 - 535
[6] Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom
O'Reilly, Maeve A.
Sanderson, Robin
Wilson, William
Burns, David
Besley, Caroline
Creasey, Thomas
Uttenthal, Ben
Elliot, Johnathon
Roddie, Claire
Kuhnl, Andrea
Paneesha, Shankara
Seymour, Frances
Iyengar, Sunil
Rubio, Lourdes
Wilson, Matthew
Boyle, Stephen
Cheok, Kathleen Pl
Collins, Graham P.
Johnson, Rod
McMillan, Andrew K.
BLOOD, 2022, 140 : 7519 - 7521
[7] IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A REAL-LIFE, RETROSPECTIVE, MULTICENTER TRIAL ON BEHALF OF THE "RTL" (REGIONAL TUSCAN LYMPHOMA NETWORK)
Cencini, E.
Mecacci, B.
Morelli, F.
Ghio, F.
Romano, I.
Birtolo, S.
Simonetti, F.
Zoi, V.
Moretti, S.
Sant'Antonio, E.
Cuccaro, A.
Santini, S.
Kovalchuk, S.
Puccini, B.
Galimberti, S.
Bocchia, M.
Fabbri, A.
HAEMATOLOGICA, 2021, 106 (10) : 142 - 143
[8] Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
Zhang, Yuchen
Liu, Panpan
Cai, Jun
Jing, Hongmei
Zou, Liqun
Huang, Huiqiang
Wu, Yuanbin
Li, Wenyu
Zhong, Liye
Jin, Xueli
Ye, Xu
Feng, Ru
Zhang, Huilai
Zhang, Liling
Lin, Lie
Sun, Xiuhua
Tian, Yuyang
Xia, Zhongjun
Li, Zhiming
Huang, He
Xia, Yi
Cai, Qingqing
CANCER MEDICINE, 2022, 11 (22): : 4134 - 4145
[9] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
Maruyama, Dai
Omi, Ai
Nomura, Fumi
Touma, Tokiko
Noguchi, Yukiko
Takebe, Kyoko
Izutsu, Koji
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (02) : 146 - 155
[10] Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance
Dai Maruyama
Ai Omi
Fumi Nomura
Tokiko Touma
Yukiko Noguchi
Kyoko Takebe
Koji Izutsu
International Journal of Hematology, 2024, 119 : 146 - 155

← 1 2 3 4 5 →